Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D. Hofmann WK, et al. Among authors: seipelt g. Ann Hematol. 2002 Oct;81(10):570-4. doi: 10.1007/s00277-002-0542-8. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424538 Clinical Trial.
Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
Ganser A, Maurer A, Contzen C, Seipelt G, Ottmann OG, Schadeck-Gressel C, Kolbe K, Haas R, Zander C, Reutzel R, Hoelzer D. Ganser A, et al. Among authors: seipelt g. Ann Hematol. 1996 Apr;72(4):237-44. doi: 10.1007/s002770050166. Ann Hematol. 1996. PMID: 8624378 Clinical Trial.
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D. Ganser A, et al. Among authors: seipelt g. Ann Hematol. 2000 Jan;79(1):30-5. doi: 10.1007/s002770050005. Ann Hematol. 2000. PMID: 10663618 Clinical Trial.
Cytokine therapy for myelodysplastic syndrome.
Seipelt G, Ottmann OG, Hoelzer D. Seipelt G, et al. Curr Opin Hematol. 2000 May;7(3):156-60. doi: 10.1097/00062752-200005000-00005. Curr Opin Hematol. 2000. PMID: 10786652 Review.
79 results